KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Cash from Investing Activities (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Cash from Investing Activities data on record, last reported at -$288.1 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 64.95% year-over-year to -$288.1 million; the TTM value through Dec 2025 reached -$945.4 million, up 74.92%, while the annual FY2025 figure was -$945.4 million, 74.92% up from the prior year.
  • Cash from Investing Activities reached -$288.1 million in Q4 2025 per VRTX's latest filing, down from -$117.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $175.6 million in Q4 2022 and bottomed at -$2.1 billion in Q1 2024.
  • Average Cash from Investing Activities over 5 years is -$426.0 million, with a median of -$211.0 million recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: skyrocketed 231.04% in 2022, then crashed 3495.29% in 2023.
  • A 5-year view of Cash from Investing Activities shows it stood at -$134.0 million in 2021, then surged by 231.04% to $175.6 million in 2022, then plummeted by 604.84% to -$886.5 million in 2023, then rose by 7.29% to -$821.9 million in 2024, then skyrocketed by 64.95% to -$288.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$288.1 million in Q4 2025, -$117.0 million in Q3 2025, and -$484.5 million in Q2 2025.